Senniappan S, Shanti B, Hussain K. Hyperinsulinaemic hypoglycaemia. Genetic mechanisms, diagnosis and management. J Inherit Metab Dis. 2012;35(4):589–601. https://pubmed.ncbi.nlm.nih.gov/22231386. https://doi.org/10.1007/s10545-011-9441-2.

Galcheva S, Demirbilek H, Al-Khawaga S, Hussain K. The genetic and molecular mechanisms of congenital hyperinsulinism. Front. Endocrinol. (Lausanne).2019;10:111. https://pubmed.ncbi.nlm.nih.gov/30873120. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6401612. https://doi.org/10.3389/fendo.2019.00111.

Mitrofanova, L, Perminova A, Ryzhkova D, Sukhotskaya A, Bairov V, Nikitina. Differential morphological diagnosis of various forms of congenital hyperinsulinism in children. Front. Endocrinol. (Lausanne). 2021;12:710947. https://pubmed.ncbi.nlm.nih.gov/34497584. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8419459. https://doi.org/10.3389/fendo.2021.710947.

Sharma R, Roy K, Satapathy A, et al. Molecular characterization and management of congenital hyperinsulinism: A tertiary centre experience. Indian Pediatr. 2022;59(2):105-9. https://pubmed.ncbi.nlm.nih.gov/34992182. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8913199. https://doi.org/10.1007/s13312-022-2438-0.

Hussain K, Aynsley-Green A, Stanley CA. Medications used in the treatment of hypoglycaemia due to congenital hyperinsulinism of infancy (HI). Pediatr Endocrinol Rev.2004; 2 Suppl 1:163-7. https://pubmed.ncbi.nlm.nih.gov/16456495.

Maria G, Antonia D, Michael A, et al. Sirolimus: Efficacy and complications in children with hyperinsulinemic hypoglycemia: A 5-year follow-up study. J. Endocr. Soc. 2019;3(4):699-713. https://pubmed.ncbi.nlm.nih.gov/30882046. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411415. https://doi.org/10.1210/js.2018-00417.

Ng CM, Tang F, Seeholzer SH, Zou Y, De León DD. Population pharmacokinetics of exendin-(9-39) and clinical dose selection in patients with congenital hyperinsulinism. Br J Clin Pharmacol. 2018;84(3):520-32. https://pubmed.ncbi.nlm.nih.gov/29077992. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5809353. https://doi.org/10.1111/bcp.13463.

Salomon-Estebanez M, Yau D, Dunne M, et al. Corrigendum: Efficacy of dose-titrated glucagon infusions in the management of congenital hyperinsulinism: A case series. Front Endocrinol (Lausanne). 2020;11:441. https://pubmed.ncbi.nlm.nih.gov/33013678. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7494759. https://doi/org/10.3389/fendo.2020.00441. Erratum in: Front Endocrinol (Lausanne). 2020;11:614734. https://pubmed.ncbi.nlm.nih.gov/33312164.

Dastamani A, Guemes M, Pitfield C, et al. Variation in glycemic outcomes in focal forms of congenital hyperinsulinism - The UK perspective. J Endocr Soc. 2022;6(6):bvac033. https://pubmed.ncbi.nlm.nih.gov/35592516. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9113085. https://doi.org/10.1210/jendso/bvac033.

States LJ, Christopher Davis J, Hamel SM, Becker SA, Zhuang, H. 18F-6-Fluoro-L-Dopa PET/CT imaging of congenital hyperinsulinism. J Nucl Med. 2021;62(Suppl 2):51S-6. https://pubmed.ncbi.nlm.nih.gov/34230074. https://doi.org/10.2967/jnumed.120.246033.

Haris B, Saraswathi S, Hussain K. Somatostatin analogues for the treatment of hyperinsulinaemic hypoglycemia. Ther Adv Endocrinol Metab. 2020;11:2042018820965068. https://pubmed.ncbi.nlm.nih.gov/33329885. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7720331. https://doi.org/10.1177/2042018820965068.

Novokreshhennyx EE, Gubaeva DN, Melikyan MA. The use of long-acting somatostatin analogs in congenital hyperinsulinism. Probl Endokrinol (Mosk). 2024;66(5):70-8. https://pubmed.ncbi.nlm.nih.gov/33369374. https://doi.org/10.14341/probl12654.

Cao B, Di W, Su C, et al. Efficacy and safety of octreotide treatment for diazoxide-unresponsive congenital hyperinsulinism in China. Pediatr Investig. 2020;4(1):29-36. https://pubmed.ncbi.nlm.nih.gov/32851339. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7331369. https://doi.org/10.1002/ped4.12175.

Melikyan MA, Gubaeva DN, Kareva MA. Continuous subcutaneous infusion of somatostatin analogues in the treatment of congenital hyperinsulinism. Probl Endokrinol (Mosk). 2020;66(3):81-7. https://pubmed.ncbi.nlm.nih.gov/33351342. https://doi.org/10.14341/probl12421.

Gubaeva, DN, Melikyan M, Ryzhkova D, et al. Clinical, genetic, and radionuclide characteristics of the focal form of congenital hyperinsulinism. Probl Endokrinol (Mosk). 2019;65(5):319-29. https://pubmed.ncbi.nlm.nih.gov/32202736. https://doi.org/10.14341/probl10317.

Dastamani A, Güemes M, Pitfield C, et al. The use of a long-acting somatostatin analogue (Lanreotide) in three children with focal forms of congenital hyperinsulinaemic hypoglycaemia. Horm Res Paediatr. 2019;91(1):56–61. https://pubmed.ncbi.nlm.nih.gov/30114684. https://doi.org/10.1159/000491101.

Sokolov Y, Melikyan M, Efremenkov A, Gubaeva D, Druzhinin V, Osmanov. Laparoscopic resections of the pancreas in children with hyperinsulinism. Russ J Pediatr Surg. 2020;24(6):363-9. https://jps-nmp.ru/jour/article/view/4/4.

van Der Steen I, van Albada ME, Mohnike K, et al. A Multicenter experience with long-acting somatostatin analogues in patients with congenital hyperinsulinism. Horm Res Paediatr. 2018;89(2):82-9. P MID: 29241206. https://doi.org/10.1159/000485184.

Kassem SA, Ariel I, Thornton PS, Scheimberg I, Glaser B. Beta-cell proliferation and apoptosis in the developing normal human pancreas and in hyperinsulinism of infancy. Diabetes. 2000;49(8):1325-33. https://pubmed.ncbi.nlm.nih.gov/10923633. https://doi.org/10.2337/diabetes.49.8.1325.